SynthesisFrontiers in oncology2025

The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.

Yun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.